Abstract
In the present study the efficacies of therapy with insulin, sulphonylurea or insulin + metformin on NIDDM patients are compared. One group which was on a definite dose of insulin therapy, but with uncontrolled diabetes was treated by doubling the insulin dose, a second group whose diabetes was not controlled by glibenclamide was switched over to another sulphonylurea viz; glimepiride and a third group whose diabetes was not controlled by insulin therapy was switched over to a combination therapy with insulin +metformin. After recording their initial blood parameters all the groups were treated as above for 3 months, and the parameters were again determined. The fasting blood sugar and serum lipids of the first group were controlled significantly, but the values were far above normal range. However HDL Cholesterol and atherogenic index were near normal range. In glimepiride treated group, none of the parameters showed any amelioration. In the combined therapy group, control of blood sugar and atherogenic index was more or less the same as for group 1, but hyperlipidemia remained slightly above that of the same. From the findings we can infer that in long term diabetes treatment higher doses of insulin and combined therapy with insulin and metformin may be more beneficial than with low doses of insulin or sulfonyl urea alone
Similar content being viewed by others
References
Van der wal PS, Draegar KE, Van Iperen AM, Martini C, Aarsen M, Heine RJ. B cell response to oral glimepiride administration during and following hyperglycemic clamp in NIDDM patients. Diabet Met 1997; 14: 556.
Geisen K, Vegh A, Krause E, Papp G. Cardiovascular effects of conventional sulphonylureas and glimepiride. Horm Metab Res 1996; 28: 496–507.
Henry RR, Edelman SV. Advances in treatment of NIDDM in the elderly. Geriatrics 1992; 47: 24.
Galloway JA. Treatment of NIDDM with insulin agonists or substitutes. Diabetes Care 1990; 13: 1209–1239.
Ferrannini E, Stern MP, Galvan AQ, Mitchell BD, Haffner SM. Impact of associated conditions in glycemic control of NIDDM patients. Diabetes Care 1992; 15: 508.
Augusti KT, Sunil MP, Abraham A, Thomas S, Chemmanam V. A comparative study on the effects of diet and exercise, metformin and metformin +pioglitazone treatment on NIDDM patients. Ind J Clin Biochem 2007; 22(2): 65–69.
Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969; 6: 24–27.
Chiamori N, Henry R. Total cholesterol, Zlatkis (modified) method, in: Gradwohl’s Clinical Laboratory Methods and Diagnosis. Edited by Frankel S, Reitman S, Sonnenwirth AC (The C.V. Mosby company, Saint Louis) 1963, 263p.
Warnick RG, Albers JA. A comprehensive evaluation of the heparin- manganese precipitating procedures for estimating high density lipoprotein cholesterol. J Lip Res 1978; 19: 65–76.
Chaudhary K. Cholesterol evaluation in: Biochemical techniques. Jaypee Medical Publishers 1989 pp 102–103.
Van Handel E, Zilversmit DB. Serum triglycerides: Micromethod; in: Gradwohl’s Clinical Laboratory Methods and Diagnosis. Edited by Frankel S, Reitman, S, Sonnenwirth AC (The Mosby Company, Saint Louis) 1963: 263.
Armitage P, Berry G. Statistical Methods in Medical Research, 2nd ed. Black Well Scientific Publications, Oxford 1987; 186–196pp.
Ginsberg HN. Relationship between diabetes mellitus and coronary artery disease. Clin Diabetes 1988; 6Supp (4); 73–94.
Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki-Jarvinen H. Insulin therapy induces antiatherogenic changes of serum lipoprotein in NIDDM patients. Arteriosclerosis 1988; 8: 168–177.
Dunn FL. Treatment of lipid disorders in DM. Med Clin North Am 1988; 72(6); 1379–1398.
Reaven GM. Abnormal lipoprotein metabolism in NIDDM; Pathogenesis and treatment. Am J Med 1987; 83Suppl 3&4: 31–40.
Melander A, Lebovitz HE, Faber UK. Sulphonyl ureas: Why, which and how? Diabetes Care 1990; 13Suppl 3: 18–25.
Hermann LS, Karlson JE, Sijostrand A. Perspective comparative study in NIDDM using metformin and glibenclamide with special reference to lipid profiles. Eur J Clin 1991; 41: 263–265.
Purnell JQ, Hirsch IB. New oral therapies for type 2 diabetes. Am Family Physician 1997; 56: 1835.
Bell DSH, Mayo MS. Outcome of metformin facilitated reinitiation of oral antidiabetic therapy in insulin treated patients with NIDDM. Endocrine Practice 1997; 3: 73.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Valsaraj, S., Augusti, K.T., Chemmanam, V. et al. Effects of insulin, glimepiride and combination therapy of insulin and metformin on blood sugar and lipid profile of NIDDM patients. Indian J Clin Biochem 24, 175–178 (2009). https://doi.org/10.1007/s12291-009-0031-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-009-0031-0